

## BASELINE TERIPARATIDE PATIENT PRIOR APPROVAL FORM

In accordance with the contract between Oxford University Hospitals Trust and Oxfordshire CCG, treatment with teriperatide in line with NICE Technology Appraisal 161 "Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriperatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women" should not be commenced until prior approval has been agreed by the Oxfordshire Medicines Management Team.

**All boxes must be completed. Where the information is unavailable please put N/A.**

### Patient Details

**Name:**

**Sex:**

**Date of birth:**

**NHS number:**

**Hospital number**

**OUH clinician requesting initiation of treatment**

**GP Practice**

**Anticipated date to commence treatment with teriperatide:**

### Clinical Details

**1. Age at menopause:**

**2. Date of diagnosis of osteoporosis**

**3. Baseline bone mineral density and site at diagnosis**

**4. Contraindications to teriperatide treatment?**

	Yes	No
Prior radiotherapy		

Hyperparathyroidism		
Paget's disease		
Active/recent urolithiasis		
Skeletal malignancy/ bone metastases		

#### Renal function

Sr Cr	
Calc CrCl A CrCl of 30ml/min should usually contraindicate teriperatide	

Alkaline phosphatase	
Serum calcium	

#### Caution:

Is patient taking digoxin?

#### 5. Previous osteoporosis therapy

	Date started	Date stopped	Reason for discontinuation or for never starting
Alendronate			
Risedronate			
Etidronate			
Strontium ranelate			
Denosumab			
Other (please name)			

#### 6. Fracture History – non-spinal fractures

Fracture site Non spinal	Date of fracture	Was it a fragility fracture as defined by NICE i.e. sustained as the result of a force equivalent to the force of a fall from a height equal to, or less than, that of an ordinary chair?


## 7. Spinal Fractures

Site of spinal fracture	Date of fracture (if known)	Date of X-ray detection (if known)

## 8. Bone Mineral Density (DXA) scores

Site	Date	T Score
Spine L1 – L4		
Femoral Neck		
Total Hip		

For patients over 75 years who have NEVER had the BMD measured state why this is and also indicate clinical risk factors

Measurement inappropriate or unfeasible	Reason
Parental history of hip fracture	
Alcohol intake of 4 or more units daily	
Rheumatoid arthritis	
Indicators of low BMD	

**9 Calcium and vitamin D status**

**10. Other relevant clinical data including secondary causes of osteoporosis (drugs and medical conditions – please give length of history)**

If Patient does NOT fulfil NICE criteria and you consider that there are grounds for seeking funding as an exception to the criteria you must additionally complete an Individual Funding Request Form which is available from [priorities.oxfordshirepct@nhs.net](mailto:priorities.oxfordshirepct@nhs.net)

Note; For funding on the basis of 'exceptionality' you must answer the question – "why should this patient be funded for treatment when others with a broadly similar condition would not be".